Arbutus Biopharma Files 8-K
Ticker: ABUS · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financials
TL;DR
Arbutus Biopharma filed an 8-K on Nov 15, 2024, with financial updates.
AI Summary
Arbutus Biopharma Corp. filed an 8-K on November 15, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceuticals Corp, is incorporated in British Columbia, Canada, and its principal executive offices are located in Warminster, Pennsylvania.
Why It Matters
This filing indicates routine corporate reporting, including financial updates and other significant events that may impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain any immediately alarming or significant new information.
Key Numbers
- 001-34949 — SEC File Number (Identifies the company's filing with the SEC)
- 98-0597776 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- November 15, 2024 (date) — Date of earliest event reported
- Warminster, Pennsylvania (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the significance of the former company name 'Tekmira Pharmaceuticals Corp'?
The filing states that Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp, with name changes occurring on June 7, 2011, and October 3, 2008.
What is the primary business of Arbutus Biopharma Corp?
The Standard Industrial Classification code provided is 'PHARMACEUTICAL PREPARATIONS [2834]', indicating the company operates in the pharmaceutical sector.
Where are Arbutus Biopharma Corp.'s principal executive offices located?
The principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania, 18974.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is November 15, 2024.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-11-15 11:03:13
Filing Documents
- f8k_111524.htm (8-K) — 16KB
- exh_991.htm (EX-99.1) — 14KB
- exh_992.htm (EX-99.2) — 18KB
- exh_993.htm (EX-99.3) — 32KB
- exh993_01.jpg (GRAPHIC) — 95KB
- exh993_02.jpg (GRAPHIC) — 255KB
- exh993_03.jpg (GRAPHIC) — 182KB
- exh993_04.jpg (GRAPHIC) — 137KB
- exh993_05.jpg (GRAPHIC) — 152KB
- exh993_06.jpg (GRAPHIC) — 164KB
- exh993_07.jpg (GRAPHIC) — 100KB
- exh993_08.jpg (GRAPHIC) — 85KB
- exh993_09.jpg (GRAPHIC) — 112KB
- exh993_10.jpg (GRAPHIC) — 126KB
- exh993_11.jpg (GRAPHIC) — 170KB
- exh993_12.jpg (GRAPHIC) — 174KB
- exh993_13.jpg (GRAPHIC) — 188KB
- exh993_14.jpg (GRAPHIC) — 216KB
- exh993_15.jpg (GRAPHIC) — 110KB
- exh993_16.jpg (GRAPHIC) — 88KB
- exh993_17.jpg (GRAPHIC) — 145KB
- exh993_18.jpg (GRAPHIC) — 114KB
- exh993_19.jpg (GRAPHIC) — 167KB
- exh993_20.jpg (GRAPHIC) — 106KB
- exh993_21.jpg (GRAPHIC) — 80KB
- exh993_22.jpg (GRAPHIC) — 165KB
- exh993_23.jpg (GRAPHIC) — 76KB
- 0001171843-24-006400.txt ( ) — 4712KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_111524_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On November 15, 2024, Arbutus Biopharma Corporation ("Arbutus" or the "Company") issued a press release announcing new data from its IM-PROVE I Phase 2a clinical trial (AB-729-201) showing that six doses of imdusiran, the Company's RNAi therapeutic candidate, and 24 weeks of pegylated interferon alfa-2 (IFN), a standard-of-care immunomodulator, added to ongoing nucleos(t)ide analogue (NA) therapy, led to a functional cure rate of 50% (3/6) in HBeAg-negative patients with baseline HBsAg levels less than 1000 IU/mL, and an overall functional cure rate of 25% (3/12). Patients with HBsAg levels less than 1000 IU/mL represent a significant portion of the cHBV population. These data will be presented as a late-breaker poster presentation on November 18, 2024 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2024. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. On November 15, 2024, Arbutus and Barinthus Biotherapeutics plc, issued a press release announcing new preliminary data from the Phase 2a IM-PROVE II clinical trial (AB-729-202) of people with chronic hepatitis B virus (cHBV) at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2024. A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated by reference herein. On November 15, 2024, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.3 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated November 15, 2024 99.2 Press release dated November 15, 2024 99.3 Presentation dated November 15, 2024 104 Cover page interactive data file (formatted as inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: November 15, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer